ReviR Therapeutics

ReviR Therapeutics (溪砾科技) is a Chinese biotech startup founded in May 2021 that develops AI-driven, orally deliverable small-molecule drugs targeting RNA to treat genetic diseases, with a focus on neurodegenerative and rare neurological conditions . The company's core platform, VoyageR, combines machine learning with RNA structural biology to predict splicing targets, model molecular activity, and generate optimized drug candidates—aiming to overcome the "undruggable" protein problem by intervening at the RNA level upstream . Its pipeline includes programs for Huntington's disease (HD), Charcot-Marie-Tooth disease type 1A (CMT1A), and amyotrophic lateral sclerosis (ALS), among others .

The company has raised significant venture backing across multiple rounds, including a $30 million Series A in July 2024 led by Longpan Investment with follow-on from 5Y Capital, CDH Investments, and YaYi Capital, plus strategic investors XtalPi and the CMT Research Foundation . Earlier investors include BlueRun Ventures, which backed ReviR at the seed stage, as well as Shunwei Capital, Sky9 Capital, and Tiantu Capital . ReviR maintains a close strategic partnership with XtalPi, the AI drug discovery firm, with whom it has collaborated on pipeline programs planned for clinical advancement .